What are Cardiac Myosin Inhibitor [EPC] drugs?

Cardiac Myosin Inhibitor [EPC] drugs are pharmacologic agents that share a common mechanism (typically targeting cardiac myosin). 2 are currently marketed, with 2 more in clinical development.

What are the marketed Cardiac Myosin Inhibitor [EPC] drugs?

Marketed Cardiac Myosin Inhibitor [EPC] drugs include Camzyos, Camzyos.

Cardiac Myosin Inhibitor [EPC]

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 marketed 1 in Phase 3 1 in Phase 2

This page covers all Cardiac Myosin Inhibitor [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting cardiac myosin, Myosin-7, Cardiac myosin.

Targets

cardiac myosin · Myosin-7 · Cardiac myosin

Marketed (2)

Camzyos · Bristol-Myers Squibb · Cardiovascular · 600
Mavacamten selectively inhibits cardiac myosin, reducing force-producing cross-bridge formation and improving cardiac function in HCM.
Camzyos · Myokardia Inc · Cardiovascular
Camzyos works by inhibiting the Myosin-7 protein, which is involved in the thickening of heart muscle cells.

Phase 3 pipeline (1)

TNX-103 · Tenax Therapeutics, Inc. · Cardiovascular
TNX-103 is a cardiac myosin inhibitor that reduces the force of heart muscle contraction to improve cardiac function in heart failure patients.

Phase 2 pipeline (1)

CK-2017357 · Cytokinetics · Cardiovascular
CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility.

Patent intelligence

cardiac myosin inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates